I-Mab (NASDAQ:IMAB – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
I-Mab (NASDAQ:IMAB – Get Free Report) last released its earnings results on Wednesday, August 28th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.44. On average, analysts expect I-Mab to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
I-Mab Stock Performance
Shares of IMAB opened at $1.09 on Thursday. I-Mab has a 52 week low of $0.99 and a 52 week high of $2.54. The business has a 50-day simple moving average of $1.20 and a two-hundred day simple moving average of $1.44.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on IMAB
I-Mab Company Profile
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Featured Stories
- Five stocks we like better than I-Mab
- What Are Some of the Best Large-Cap Stocks to Buy?
- What a Trump Win Looks Like for the Market Now and Into 2025
- How to buy stock: A step-by-step guide for beginners
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What is Forex and How Does it Work?
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.